PUBLIC COMPANY
saveTaiho Oncology Inc
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 5pipeline
5
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 11Phase 32Marketed1Unknown
Marketed
(tipiracil hydrochloride + trifluridine)
Adenocarcinoma Of The Gastroesophageal Junction
Marketedfutibatinib
Bile Duct Cancer (Cholangiocarcinoma)
Fibroblast growth factor receptor
Phase 3(azacitidine + cedazuridine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Phase 1TAS-2940
Solid Tumor
drugLYTGOBI
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 4d ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 4d ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 4d ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 3mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that